- Rentschler Biopharma SE announced a strategic realignment, exiting the cell and gene therapy sector and closing its Stevenage, UK site.
- The company will focus on biologics manufacturing, supported by recent investments in Laupheim, Germany, and Milford, MA, USA.
Rentschler Biopharma SE, a global CDMO, has announced a strategic shift, withdrawing from cell and gene therapy development and closing its Stevenage, UK facility. The move aligns with the company’s long-term growth strategy and response to evolving market conditions.
The decision follows a comprehensive review of market demand, which has been slower than expected for cell and gene therapies. Benedikt von Braunmühl, CEO of Rentschler Biopharma, stated, “The cell and gene therapy market has experienced slower-than-expected growth, with demand across the industry not meeting our expectations. Following a comprehensive strategic review, we are focusing our efforts on areas where we see the greatest demand and potential to create value sustainably.”
As part of its refocused strategy, the company will prioritise biologics manufacturing. Recent investments include Rentschler Biopharma’s largest-ever expansion at its Laupheim, Germany headquarters, aimed at enhancing production efficiency. Additionally, its Milford, MA site in the US is now fully operational with a new production line featuring four 2,000 L single-use bioreactors.
The company has expressed gratitude to its Stevenage-based employees and committed to supporting them during this transition. Moving forward, Rentschler Biopharma will continue evaluating opportunities in biologics while leveraging its expertise in biopharmaceutical manufacturing.